Ann: FOURTH SITE IN HEPATITIS C CLINICAL TRIAL, page-3

Hello J8,

"My view, they have not dosed patient 7 or 8 yet"

I think you are exactly right. If there first three sites were doing well, then why open a fourth? I suspect that suitable candidates are in short supply and a difficulty in getting patients for trials contributed to the haste to complete the last capital raising. News about effacy seems to drift futher into the distant future. Please Peter, under promise and over deliver; not the other way round.